MedPath

BOSTON SCIENTIFIC CORPORATION

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

533

Active:28
Completed:371

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:17
Phase 2:29
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (372 trials with phase data)• Click on a phase to view related trials

Not Applicable
231 (62.1%)
Phase 4
47 (12.6%)
Phase 3
45 (12.1%)
Phase 2
29 (7.8%)
Phase 1
17 (4.6%)
Early Phase 1
2 (0.5%)
phase_1_2
1 (0.3%)

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

Not Applicable
Not yet recruiting
Conditions
Heart Failure - NYHA II - IV
First Posted Date
2025-07-17
Last Posted Date
2025-07-17
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
850
Registration Number
NCT07069738

Safety and Effectiveness of Orbera365™ Intragastric Balloon System

Not yet recruiting
Conditions
Obesity
First Posted Date
2025-07-14
Last Posted Date
2025-07-14
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
200
Registration Number
NCT07062094

Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area

Not Applicable
Not yet recruiting
Conditions
Anastomotic Leaks
Hartmanns Stump Leakage
First Posted Date
2025-06-25
Last Posted Date
2025-07-18
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
66
Registration Number
NCT07035431
Locations
🇺🇸

Barnes Jewish Hospital, Saint Louis, Missouri, United States

🇺🇸

Mount Sinai, New York, New York, United States

🇺🇸

New York Presbyterian / Columbia University Irving Medical Center, New York, New York, United States

and more 3 locations

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass

Not Applicable
Not yet recruiting
Conditions
Weight Regain
Weight Loss
First Posted Date
2025-06-11
Last Posted Date
2025-06-11
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
108
Registration Number
NCT07015424
Locations
🇺🇸

University of South Florida, Tampa, Florida, United States

Stone and Laser Therapies Post-Market Study (SALT)

Recruiting
Conditions
Benign Prostate Hypertrophy(BPH)
Renal Calculi
Ureteral Stones, Kidney Stones
Urinary Tract Procedure
Calculi, Urinary
First Posted Date
2025-05-21
Last Posted Date
2025-07-24
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
238
Registration Number
NCT06982235
Locations
🇺🇸

University of Miami Hospital, Miami, Florida, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 101
  • Next

News

VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention

The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.

VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment

The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.

VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment

• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.

Senseonics' Eversense 365 CGM System Receives FDA Clearance for One-Year Use

Senseonics and Ascensia Diabetes Care secured FDA clearance for Eversense 365, a next-generation continuous glucose monitoring (CGM) system, for adults with type 1 and type 2 diabetes.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.